FDA approves first standalone nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Healio32m
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Hosted on MSN12m
FDA Clears Spravato For Monotherapy Depression Treatments
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
BioPharma Dive13m
J&J oncology sales grow, but shares slide on outlook
CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...
Marijuana Moment28m
Virginia Senate Panel Advances Proposal To Fund Psychedelic Therapy Trials And Pave Path To Broader Reform
A Virginia Senate subcommittee has advanced a bill that would help fund clinical trials involving veterans and “breakthrough therapies” as designated by the Food and Drug Administration ...